TABLE 1.
Characteristics | OR (95% CI)a |
||
---|---|---|---|
Crude risk | Adjusted risk |
||
Model 1 | Model 2 | ||
Patient characteristics at surgery | |||
Age, yrs | |||
<60 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
60–69 | 0.87 (0.24–3.09) | 2.45 (0.26–22.72) | 2.59 (0.28–24.38) |
70−74 | 2.40 (0.65–8.81) | 12.55 (1.06–149.26) | 14.24 (1.21–167.40) |
≥75 | 1.96 (0.56–6.91) | 8.68 (0.79–95.19) | 10.55 (0.99–112.75) |
Sex | |||
Female | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
Male | 0.76 (0.35–1.67) | 0.47 (0.14–1.56) | 0.44 (0.13–1.41) |
ASA score | |||
I (healthy) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
II (mild) | 0.80 (0.32–2.02) | 2.29 (0.45–11.78) | 2.69 (0.56–12.96) |
III-IV (severe or worse) | 2.01 (0.65–6.19) | 4.10 (0.60–27.92) | 4.99 (0.79–31.45) |
Preoperative treatment | |||
None | 1.00 (ref) | 1.00 (ref) | |
Radiotherapy | 1.17 (0.74–1.84) | 0.71 (0.12–4.15) | |
Tumor characteristics | |||
Localization | |||
Colon right | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
Colon left | 0.47 (0.16–1.32) | 0.78 (0.16–3.82) | 0.76 (0.16–3.63) |
Rectum | 0.72 (0.28–1.84) | 2.03 (0.33–12.63) | 1.61 (0.36–7.21) |
Mucinous cancer | |||
No | 1.00 (ref) | 1.00 (ref) | |
Yes | 0.83 (0.24–2.93) | 0.50 (0.05–5.39) | |
TNM stage | |||
III | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
IV | 10.8 (3.68–31.72) | 44.67 (5.53–360.63) | 49.32 (5.86–415.12) |
Grade of differentiation | |||
Low | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
Medium | 0.20 (0.07–0.54) | 0.23 (0.05–0.98) | 0.24 (0.06–1.00) |
High | 0.21 (0.05–0.97) | 0.09 (0.01–1.24) | 0.10 (0.01–1.27) |
Surgical characteristics | |||
Period of surgery | |||
1997−2005 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
2006−2010 | 0.54 (0.21–1.37) | 0.44 (0.10–1.92) | 0.44 (0.10–1.89) |
2011−2017 | 0.59 (0.21–1.65) | 1.19 (0.22–6.47) | 1.08 (0.22–5.36) |
Radical operation | |||
No | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
Yes | 0.05 (0.01–0.41) | 0.13 (0.01–1.51) | 0.12 (0.01–1.34) |
Model 1 values are adjusted for all variables. Model 2 values are adjusted for all variables except for preoperative treatment and mucinous cancer. ref, reference.